https://corcept.com/wp-content/uploads/COR-logo.svg00jeremiah@devisedesigns.comhttps://corcept.com/wp-content/uploads/COR-logo.svgjeremiah@devisedesigns.com2023-11-13 00:00:002023-11-13 00:00:00Miricorilant reduced liver fat and cardiometabolic disease markers in a phase 1b, open-label dose-finding study in patients with non-alcoholic steatohepatitis (NASH)
